Attovia 制药

最新新闻

• Morgan Stanley Maintains Attovia Therapeutics(ATTO.US) With Buy Rating, Maintains Target Price $39
  \u5e02\u573a\u8d44\u8baf · 2026/9/3
• LifeSci Capital Initiates Attovia Therapeutics(ATTO.US) With Buy Rating, Announces Target Price $45
  \u5e02\u573a\u8d44\u8baf · 2026/8/31
• 评级变动
  RBC Capital Initiates Attovia Therapeutics(ATTO.US) With Buy Rating, Announces Target Price $45
  \u5e02\u573a\u8d44\u8baf · 2026/8/31
• 评级变动
  Morgan Stanley Initiates Attovia Therapeutics(ATTO.US) With Buy Rating, Announces Target Price $39
  \u5e02\u573a\u8d44\u8baf · 2026/8/31
• LifeSci Capital Maintains Attovia Therapeutics(ATTO.US) With Buy Rating, Maintains Target Price $45
  \u5e02\u573a\u8d44\u8baf · 2026/9/5
• 评级变动
  Analysts Offer Insights on NA Companies: Fastenal Company (FAST) and Attovia Therapeutics, Inc. (ATTO)
  TipRanks · 2026/9/3
• Citi Maintains Attovia Therapeutics(ATTO.US) With Buy Rating, Maintains Target Price $30
  \u5e02\u573a\u8d44\u8baf · 2026/9/4
• RBC Capital Maintains Attovia Therapeutics(ATTO.US) With Buy Rating, Maintains Target Price $45
  \u5e02\u573a\u8d44\u8baf · 2026/9/3
• 评级变动
  Citi Initiates Attovia Therapeutics(ATTO.US) With Buy Rating, Announces Target Price $30
  \u5e02\u573a\u8d44\u8baf · 2026/8/31
• 评级变动
  Analysts Offer Insights on NA Companies: Attovia Therapeutics, Inc. (ATTO) and Navan, Inc. Class A (NAVN)
  TipRanks · 2026/9/4

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。